ZMC I O ZMUC supplier risk profile Q1 2026: China-focused pharma importer with A-grade compliance.
ZMC I O ZMUC imported 85 shipments in Q1 2026 across 3 suppliers and 3 source countries. China dominated the footprint with 70 shipments (82% share), followed by South Korea with 9 shipments and Singapore with 6 shipments. The importer's primary supplier is ZHEJIANG MEDICINE, which accounts for the majority of inbound volume across all three sourcing locations. No HS codes were recorded in the dataset, limiting visibility into product categories.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
ZMC I O ZMUC shows no sanctions watchlist matches and no suppliers with detected forced-labor exposure under UFLPA proximity indicators. The importer's compliance score for Q1 2026 is 82 (grade A), reflecting a low-risk profile across monitored flags.
3 distinct tier-1 suppliers in Q1 2026
| ZHEJIANG MEDICINE | China | 70 |
| ZHEJIANG MEDICINE | South Korea | 9 |
| ZHEJIANG MEDICINE | Singapore | 6 |
Share of Q1 2026 inbound shipments by source country
0 tier-2 + 0 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.